{"schema_version":"1.0","type":"article","title":"安邦生技：免疫治療的「星鏈計畫」","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.md","lang":"zh-Hant","date":"2026-07-31","publish_at":"2026-07-31T08:00:00+08:00","updated_at":"2026-07-31","category":"商業分析系列","topic":"商業分析系列","tags":["安邦生技","ABT-301","癌症免疫治療","PD-1","轉移性大腸直腸癌","HDAC","台灣生技","腫瘤"],"summary":"一顆台灣小分子，有機會把三百億美元級PD-1藥王送進九成五患者仍無法受益的治療盲區嗎？","key_points":[],"facts":[],"sections":["01｜PD-1已經很成功，但仍有大片市場沒有訊號","02｜ABT-301如何讓腫瘤重新「連線」？","03｜三聯療法：重塑環境、打開通道、解除煞車","04｜同一條路，已在人類臨床看見過訊號","05｜第一個市場是90億美元，真正的上限在「星座效應」","06｜第二組星鏈節點：ABT-500把診斷、分層與治療連成閉環","07｜四次訊號升級，決定安邦的下一段估值","結語｜第一組臨床訊號，決定安邦是一顆衛星，或是一個星座","參考資料"],"references":[{"title":"[Starlink","source":"Technology]","date":"","url":"https://starlink.com/technology"},{"title":"[Merck","source":"2025 Form 10-K]","date":"","url":"https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"},{"title":"[BeOne Medicines","source":"2025 Full-Year Results]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm"},{"title":"[安邦生技","source":"ABT-301三聯療法Phase 1/2試驗]","date":"","url":"https://anbogen.com/en/news/cCCcD7dA6dcf"},{"title":"[Nature Medicine／PubMed","source":"MSS／pMMR大腸直腸癌三聯療法研究]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38438735/"},{"title":"[安邦生技","source":"2026 AACR ABT-301 Research]","date":"","url":"https://anbogen.com/en/news/E6B4eB8309E6"},{"title":"[Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market]","source":"","date":"","url":"https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market"},{"title":"[安邦生技","source":"創新研發：ABT-500系列、ABT-501、ABT-502與ABT-505]","date":"","url":"https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf"}],"images":[{"alt":"圖1｜免疫治療的「星鏈計畫」：ABT-301嘗試把免疫訊號送進治療盲區","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-01.png"},{"alt":"圖2｜ABT-301透過腫瘤微環境重塑，嘗試讓腫瘤重新被看見、讓免疫重新被啟動","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-02.png"},{"alt":"圖3｜三聯療法的順序式邏輯：重塑環境、打開通道、解除煞車","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-03.png"},{"alt":"圖4｜從一顆衛星到整個星座：ABT-301的跨藥物、跨癌種、跨夥伴擴張藍圖","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-04.png"},{"alt":"圖5｜安邦的資本市場想像：從66名患者的第一組訊號，走向跨癌種平台與全球合作資產","url":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-31）。安邦生技：免疫治療的「星鏈計畫」。https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-31-anbogen-immunotherapy-starlink-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}